JP4450355B2 - Urease inhibitor, ammonia odor suppressor and diaper rash inhibitor - Google Patents
Urease inhibitor, ammonia odor suppressor and diaper rash inhibitor Download PDFInfo
- Publication number
- JP4450355B2 JP4450355B2 JP2002251692A JP2002251692A JP4450355B2 JP 4450355 B2 JP4450355 B2 JP 4450355B2 JP 2002251692 A JP2002251692 A JP 2002251692A JP 2002251692 A JP2002251692 A JP 2002251692A JP 4450355 B2 JP4450355 B2 JP 4450355B2
- Authority
- JP
- Japan
- Prior art keywords
- urease
- inhibitor
- present
- ammonia
- urease inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 title claims description 78
- 239000002601 urease inhibitor Substances 0.000 title claims description 42
- 229910021529 ammonia Inorganic materials 0.000 title claims description 39
- 229940090496 Urease inhibitor Drugs 0.000 title claims description 38
- 206010012444 Dermatitis diaper Diseases 0.000 title claims description 19
- 208000003105 Diaper Rash Diseases 0.000 title claims description 19
- 239000003112 inhibitor Substances 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 33
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 18
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims description 14
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 14
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims description 14
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 8
- 201000005917 gastric ulcer Diseases 0.000 claims description 8
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 claims description 7
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims description 7
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 claims description 7
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 7
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 7
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims description 7
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims description 7
- 235000008714 apigenin Nutrition 0.000 claims description 7
- 229940117893 apigenin Drugs 0.000 claims description 7
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 claims description 7
- 229940015301 baicalein Drugs 0.000 claims description 7
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 claims description 7
- 235000008777 kaempferol Nutrition 0.000 claims description 7
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 7
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 7
- 235000009498 luteolin Nutrition 0.000 claims description 7
- 235000007708 morin Nutrition 0.000 claims description 7
- 235000005875 quercetin Nutrition 0.000 claims description 7
- 229960001285 quercetin Drugs 0.000 claims description 7
- 230000000703 anti-shock Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000000284 extract Substances 0.000 description 23
- 108010046334 Urease Proteins 0.000 description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 22
- 238000000605 extraction Methods 0.000 description 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 20
- 239000000126 substance Substances 0.000 description 19
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 17
- 235000005487 catechin Nutrition 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- YEDFEBOUHSBQBT-UHFFFAOYSA-N 2,3-dihydroflavon-3-ol Chemical class O1C2=CC=CC=C2C(=O)C(O)C1C1=CC=CC=C1 YEDFEBOUHSBQBT-UHFFFAOYSA-N 0.000 description 16
- 150000001765 catechin Chemical class 0.000 description 16
- 229930003944 flavone Natural products 0.000 description 16
- 150000002213 flavones Chemical class 0.000 description 16
- 235000011949 flavones Nutrition 0.000 description 16
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 16
- 150000002216 flavonol derivatives Chemical class 0.000 description 16
- 235000011957 flavonols Nutrition 0.000 description 16
- 241000196324 Embryophyta Species 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000003960 organic solvent Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 210000003608 fece Anatomy 0.000 description 9
- 125000006165 cyclic alkyl group Chemical group 0.000 description 8
- 238000006911 enzymatic reaction Methods 0.000 description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- 239000012488 sample solution Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- -1 hydroxyl group compound Chemical class 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000010871 livestock manure Substances 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229930013915 (+)-catechin Natural products 0.000 description 3
- 235000007219 (+)-catechin Nutrition 0.000 description 3
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 229930013783 (-)-epicatechin Natural products 0.000 description 2
- 235000007355 (-)-epicatechin Nutrition 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 240000009164 Petroselinum crispum Species 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
- 241000219995 Wisteria Species 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 238000011481 absorbance measurement Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 229940083618 sodium nitroprusside Drugs 0.000 description 2
- 229960004025 sodium salicylate Drugs 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- FTVWIRXFELQLPI-CYBMUJFWSA-N (R)-naringenin Chemical compound C1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-CYBMUJFWSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 241001070946 Chrysolepis Species 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 241001002544 Engelhardia Species 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 241001570521 Lonicera periclymenum Species 0.000 description 1
- 241001018563 Nekemias grossedentata Species 0.000 description 1
- 241000207836 Olea <angiosperm> Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000002770 Petroselinum crispum Nutrition 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 241001480057 Quercus salicina Species 0.000 description 1
- 241001016380 Reseda luteola Species 0.000 description 1
- 244000288377 Saxifraga stolonifera Species 0.000 description 1
- 235000002953 Saxifraga stolonifera Nutrition 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- RSAZYXZUJROYKR-UHFFFAOYSA-N indophenol Chemical compound C1=CC(O)=CC=C1N=C1C=CC(=O)C=C1 RSAZYXZUJROYKR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
- 235000008718 isoliquiritigenin Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Landscapes
- Pyrane Compounds (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、尿素からアンモニアを生成する反応を触媒する酵素であるウレアーゼの作用を阻害するウレアーゼ阻害剤、糞尿によるアンモニア臭を抑制するアンモニア臭抑制剤、およびアンモニアに起因するおむつかぶれを防止するおむつかぶれ防止剤に関するものである。
【0002】
【従来の技術】
ウレアーゼは、尿素が水と反応してアンモニアおよび炭酸ガスを生成する反応を触媒する酵素である。例えば、糞便中に存在する微生物が産生したウレアーゼは、ヒトや家畜の生体外に排泄された尿中に含まれる尿素と上記酵素反応を起こし、アンモニアを発生させる。したがって、ヒトや家畜の糞尿が環境中に放置された場合、上記酵素反応が起こってアンモニアが発生し、その発生したアンモニアは大気中に拡散して強い悪臭を放つことになる。
【0003】
また、糞尿で汚れたおむつ中で上記酵素反応が生じると、生成したアンモニアが皮膚のpHを上昇させ、それにより糞便中のプロテアーゼやリパーゼの活性が高まり、おむつかぶれを誘発すると考えられている。
【0004】
一方、腸内では、腸内細菌が産生するウレアーゼの作用によりアンモニアが生成され、アンモニアの有する細胞毒性により下痢等の症状を発症させることが知られている。また、胃の中では、胃に存在する細菌であるヘリコバクター・ピロリが産生するウレアーゼの作用によりアンモニアが生成され、そのアンモニアにより胃潰瘍が誘発されることが知られている。
【0005】
そこで、尿素からアンモニアが生じる可能性のある場においては、ウレアーゼの作用を阻害してアンモニアの生成を抑制することができれば、糞尿によるアンモニア臭、おむつかぶれ、下痢、胃潰瘍等を防止することが可能となる。
【0006】
ウレアーゼ阻害剤としては、現在までに、ヒドロキサム系両性界面活性剤(特開昭58−104276号)、クロロゲン酸(特開平6−183989号)や、ルスカス、グアバ、マイカイ、ルブス、ヨモギ、タマリンド、ユキノシタ、ビワ、柿等の植物抽出物(特開平8−19595号)などが報告されている。
【0007】
【発明が解決しようとする課題】
しかしながら、上記ウレアーゼ阻害剤において、ヒドロキサム系両性界面活性剤、クロロゲン酸等の合成化合物に関しては安全性の面で問題があり、上記植物抽出物に関してはウレアーゼ活性阻害効果が十分に高いものが少ないのが現状である。
【0008】
本発明は、このような実状に鑑みてなされたものであり、ウレアーゼ活性阻害効果に優れているとともに、安全性の高いウレアーゼ阻害剤、アンモニア臭抑制剤およびおむつかぶれ防止剤を提供することを目的とする。
【0009】
【課題を解決するための手段】
本発明者は、上記目的を達成するために鋭意検討を重ねた結果、フラボン類、フラボノール類、ジヒドロフラボノール類およびカテキン類が強いウレアーゼ活性阻害効果を有することを見出した。
【0010】
すなわち、本発明は、ルテオリン、バイカレイン、アピゲニン、ケンフェロール、クエルセチン、モリンおよびタキシフォリンからなる群から選ばれる1種または2種以上の化合物を有効成分として含有することを特徴とするウレアーゼ阻害剤(アンモニア臭抑制用および胃潰瘍治療用を除く。)を提供する。
【0012】
さらに、本発明は、おむつ、おしり拭き、衛生用シートまたはウェットティッシュに含有させて用いられるおむつかぶれ防止剤であって、ルテオリン、バイカレイン、アピゲニン、ケンフェロール、クエルセチン、モリンおよびタキシフォリンからなる群から選ばれる1種または2種以上の化合物を有効成分として含有することを特徴とするおむつかぶれ防止剤を提供する。
【0013】
本発明において、「植物または前記植物の抽出物」には、無処理の植物、植物の乾燥物、破砕物、粉砕物、粉末、植物を抽出原料として得られる抽出液、抽出液の希釈液もしくは濃縮液、抽出液を乾燥して得られる乾燥物、またはこれらの粗精製物もしくは精製物のいずれもが含まれる。
【0015】
本発明のウレアーゼ阻害剤によれば、その強いウレアーゼ活性阻害効果によりアンモニアの生成を抑制し、糞尿によるアンモニア臭、おむつかぶれ、下痢、胃潰瘍等を効果的に防止することができる。また、本発明のウレアーゼ阻害剤の有効成分は、主に飲用、食用、薬用等に付される植物から抽出されるものであるため、本発明のウレアーゼ阻害剤は、合成化合物と比較して安全性が高く、環境に悪影響を与える可能性も低い。
【0016】
同様に、本発明のアンモニア臭抑制剤は、その強いウレアーゼ活性阻害効果によりアンモニアの生成を抑制し、糞尿によるアンモニア臭を効果的に抑制することができる。また、本発明のおむつかぶれ防止剤は、その強いウレアーゼ活性阻害効果によりアンモニアの生成を抑制し、アンモニアに起因するおむつかぶれを効果的に防止することができる。さらに、本発明のアンモニア臭抑制剤およびおむつかぶれ防止剤の有効成分は、主に飲用、食用、薬用等に付される植物から抽出されるものであるため、本発明のアンモニア臭抑制剤およびおむつかぶれ防止剤は、合成化合物と比較して安全性が高く、環境に悪影響を与える可能性も低い。
【0017】
【発明の実施の形態】
以下、本発明について詳細に説明する。
本発明のウレアーゼ阻害剤は、薬剤として下痢、胃潰瘍等の予防・治療に使用することができるとともに、糞尿によるアンモニア臭を抑制することを目的とする場合には本発明のアンモニア臭抑制剤として使用することができ、アンモニアに起因するおむつかぶれを防止することを目的とする場合には本発明のおむつかぶれ防止剤として使用することができるため、ここではウレアーゼ阻害剤を中心に本発明を説明する。
【0018】
本発明のウレアーゼ阻害剤の有効成分は、フラボン類、フラボノール類、ジヒドロフラボノール類およびカテキン類からなる群から選ばれる1種または2種以上の化合物である。
【0019】
本発明におけるフラボン類は、下記式(1)で表される骨格を有する化合物である。
【化1】
[式(1)中、R1、R2、R3、R4、R'1、R'2、R'3、R'4およびR'5は、各々独立して水素原子、水酸基、メトキシ基または炭素数4〜10の直鎖状、分岐状もしくは環状のアルキル基を表す。]
【0020】
上記フラボン類の具体例としては、ルテオリン(式(1)において、R2、R4、R'1、R'2およびR'5が水素原子であり、R1、R3、R'3およびR'4が水酸基である化合物)、バイカレイン(式(1)において、R4、R'1、R'2、R'3、R'4およびR'5が水素原子であり、R1、R2およびR3が水酸基である化合物)、アピゲニン(式(1)において、R2、R4、R'1、R'2、R'4およびR'5が水素原子であり、R1、R3およびR'3が水酸基である化合物)等が挙げられる。
【0021】
上記フラボン類の中でも、式(1)において、R4、R'1、R'2およびR'5が水素原子または炭素数4〜10の直鎖状、分岐状もしくは環状のアルキル基、特に水素原子であり、R1およびR3が水酸基またはメトキシ基、特に水酸基である化合物が好ましく、中でも特にルテオリン、バイカレインおよびアピゲニンが好ましい。
【0022】
本発明におけるフラボノール類は、下記式(2)で表される骨格を有する化合物である。
【化2】
[式(2)中、R1、R2、R3、R4、R'1、R'2、R'3、R'4およびR'5は、各々独立して水素原子、水酸基、メトキシ基または炭素数4〜10の直鎖状、分岐状もしくは環状のアルキル基を表す。]
【0023】
上記フラボノール類の具体例としては、ケンフェロール(式(2)において、R2、R4、R'1、R'2、R'4およびR'5が水素原子であり、R1、R3およびR'3が水酸基である化合物)、クエルセチン(式(2)において、R2、R4、R'1、R'2およびR'5が水素原子であり、R1、R3、R'3およびR'4が水酸基である化合物)、モリン(式(2)において、R2、R4、R'1、R'2およびR'4が水素原子であり、R1、R3、R'3およびR'5が水酸基である化合物)等が挙げられる。
【0024】
上記フラボノール類の中でも、式(2)において、R2、R4、R'1およびR'2が水素原子または炭素数4〜10の直鎖状、分岐状もしくは環状のアルキル基、特に水素原子であり、R1、R3およびR'3が水酸基またはメトキシ基、特に水酸基である化合物が好ましく、中でも特にケンフェロール、クエルセチンおよびモリンが好ましい。
【0025】
本発明におけるジヒドロフラボノール類は、下記式(3)で表される骨格を有する化合物である。
【化3】
[式(3)中、R1、R2、R3、R4、R'1、R'2、R'3、R'4およびR'5は、各々独立して水素原子、水酸基、メトキシ基または炭素数4〜10の直鎖状、分岐状もしくは環状のアルキル基を表す。]
【0026】
上記ジヒドロフラボノール類の具体例としては、タキシフォリン(式(3)において、R2、R4、R'1、R'2およびR'5が水素原子であり、R1、R3、R'3およびR'4が水酸基である化合物)、アンペロプシン(式(3)において、R2、R4、R'1およびR'5が水素原子であり、R1、R3、R'2、R'3およびR'4が水酸基である化合物)等が挙げられる。
【0027】
上記ジヒドロフラボノール類の中でも、式(3)において、R2、R4、R'1およびR'5が水素原子または炭素数4〜10の直鎖状、分岐状もしくは環状のアルキル基、特に水素原子であり、R1、R3、R'3およびR'4が水酸基またはメトキシ基、特に水酸基である化合物が好ましく、中でも特にタキシフォリンおよびアンペロプシンが好ましい。
【0028】
本発明におけるカテキン類は、下記式(4)で表される骨格を有する化合物である。
【化4】
[式(4)中、R1、R2、R3、R4、R'1、R'2、R'3、R'4およびR'5は、各々独立して水素原子、水酸基、メトキシ基または炭素数4〜10の直鎖状、分岐状もしくは環状のアルキル基を表す。]
【0029】
上記カテキン類の具体例としては、(+)−カテキン(式(4)において、R2、R4、R'1、R'2およびR'5が水素原子であり、R1、R3、R'3およびR'4が水酸基である化合物)、(−)−エピカテキン(式(4)において、R2、R4、R'1、R'2およびR'5が水素原子であり、R1、R3、R'3およびR'4が水酸基である化合物であり、(+)−カテキンとは3位の炭素原子に結合する水酸基の向きが異なるエピマーの関係にある。)等が挙げられる。
【0030】
上記カテキン類の中でも、式(4)において、R2、R4、R'1、R'2およびR'5が水素原子または炭素数4〜10の直鎖状、分岐状もしくは環状のアルキル基、特に水素原子であり、R1、R3、R'3およびR'4が水酸基またはメトキシ基、特に水酸基である化合物が好ましく、中でも特にカテキンおよびエピカテキンが好ましい。
【0031】
ここで、本発明のウレアーゼ阻害剤の有効成分としては、上記のフラボン類、フラボノール類、ジヒドロフラボノール類およびカテキン類の中から1種の化合物を選択してもよいし、2種以上の化合物(同じ類に属する化合物が2種以上であってもよい。)を選択してもよい。
【0032】
本発明のウレアーゼ阻害剤の有効成分として使用するフラボン類、フラボノール類、ジヒドロフラボノール類およびカテキン類は、これらの成分の1種または2種以上を含有する植物から抽出することができる。
【0033】
フラボン類、フラボノール類、ジヒドロフラボノール類またはカテキン類を含有する植物の具体例としては、オリーブ(Olea europaea)、パセリ(Petroselinum sativum)、コガネバナ(Scutellaria baicalensis)、モクセイソウ(Reseda luteola)、スイカズラ(Lonicera japonica)、黄杞(Engelhardtia chrysolepis)、藤茶(Ampelopsis grossedentata),茶(Thea sinensis)、ウラジロガシ(Quercus salicina)等が挙げられる。
【0034】
抽出原料として用いる植物の構成部位は特に限定されるものではなく、例えば、葉部、枝部、根部、樹皮、種子等の構成部位を抽出原料として用いることができるが、これらのうち特に葉部を抽出原料として用いることが好ましい。
【0035】
フラボン類、フラボノール類、ジヒドロフラボノール類またはカテキン類を含有する植物からのフラボン類、フラボノール類、ジヒドロフラボノール類またはカテキン類の抽出物は、植物を生のまま、または乾燥した後、その状態で、または粉砕機を用い粉砕して溶媒抽出に供することにより得ることができる。抽出に用いる溶媒としては、水、親水性有機溶媒または水と親水性有機溶媒との混合液を、室温ないし溶媒の沸点の温度範囲で用いることが好ましい。
【0036】
抽出溶媒として使用し得る水としては、純水、水道水、井戸水、鉱泉水、鉱水、温泉水、湧水、淡水等の他、これらに各種処理を施したものが含まれる。水に施す処理としては、例えば、精製、加熱、殺菌、ろ過、イオン交換、浸透圧の調整、緩衝化等が含まれる。したがって、本発明において抽出溶媒として使用し得る水には、精製水、熱水、イオン交換水、生理食塩水、リン酸緩衝液、リン酸緩衝生理食塩水等も含まれる。
【0037】
抽出溶媒として使用し得る親水性有機溶媒としては、例えばメタノール、エタノール、プロピレンアルコール、イソプロピルアルコール等の炭素数1〜5の低級アルコール;アセトン、メチルエチルケトン等の低級脂肪族ケトン;1,3−ブチレングリコール、プロピレングリコール、イソプロピレングリコール、グリセリン等の炭素数2〜5の多価アルコールなどが挙げられ、これら親水性有機溶媒または親水性有機溶媒と水との混合溶媒などを用いることができる。
【0038】
抽出溶媒として水と親水性有機溶媒との混合溶媒を使用する場合には、親水性有機溶媒が低級アルコールのときには水10質量部に対して親水性有機溶媒1〜90質量部、親水性有機溶媒が低級脂肪族ケトンのときには水10質量部に対して親水性有機溶媒1〜40質量部、親水性有機溶媒が多価アルコールのときには水10質量部に対して親水性有機溶媒10〜90質量部を配合することが好ましい。
【0039】
本発明において、植物からフラボン類、フラボノール類、ジヒドロフラボノール類またはカテキン類を抽出するにあたり特殊な抽出方法を採用する必要はなく、室温ないし還流加熱下で、任意の装置を用いて抽出することができる。具体的には、抽出溶媒を満たした処理槽に抽出原料を投入し、時々撹拌して可溶性成分を溶出させる。その後濾過して抽出残渣を除き、得られた抽出液を濃縮、乾燥することにより、フラボン類、フラボノール類、ジヒドロフラボノール類またはカテキン類を含有する抽出物を得ることができる。
【0040】
抽出条件は、抽出溶媒として水を用いた場合は、通常40〜90℃で30分〜2時間程度であり、また、抽出溶媒として水とエタノールとの混合溶媒を用いた場合には、通常40〜80℃で30分〜2時間程度である。なお、溶媒で抽出することにより得られる抽出液は、抽出溶媒が安全性の高いものであれば、そのままウレアーゼ阻害剤の一成分として使用することができる。
【0041】
また、得られた抽出液を脱色、脱臭、活性向上等を目的として精製することもできる。精製手段としては、特に制限されず、活性炭処理、樹脂吸着処理、イオン交換樹脂処理、液−液向流分配等の方法が挙げられる。例えばセパビーズSP−207、ダイヤイオンHP−20(いずれも三菱化学(株)製)等の多孔性樹脂と濃縮液とを接触させる樹脂吸着精製法等を採用することができる。この場合、樹脂に吸着された有効成分は水、エタノール等で溶出させることができる。
【0042】
本発明では、フラボン類、フラボノール類、ジヒドロフラボノール類およびカテキン類からなる群から選ばれる1種または2種以上の化合物、またはフラボン類、フラボノール類、ジヒドロフラボノール類およびカテキン類からなる群から選ばれる1種または2種以上の化合物を含有する植物またはその植物の抽出物をウレアーゼ阻害剤の有効成分として使用するが、必要に応じてウレアーゼ阻害作用を有する他の成分を添加することもできる。
【0043】
本発明のウレアーゼ阻害剤の剤形、形態は特に制限されない。例えば、ウレアーゼ阻害剤を糞尿によるアンモニア臭の抑制またはおむつかぶれの防止に用いる場合(ウレアーゼ阻害剤をアンモニア臭抑制剤またはおむつかぶれ防止剤として使用する場合)、ウレアーゼ阻害剤は、液状、ゲル状、粉末状等の形態で使用することができ、また、ウレアーゼ阻害剤をローション、スプレー剤、ムース等に配合することもできる。このようなウレアーゼ阻害剤には、例えば、保湿剤、pH調節剤、安定化剤、界面活性剤、抗酸化剤、消臭剤、抗菌剤等の成分を配合することができる。ウレアーゼ阻害剤を液状またはゲル状の形態とする場合は、有効成分が化合物のときは、その化合物を0.00001〜1質量%、有効成分が抽出物のときは、その抽出物を0.0001〜10質量%、使用組成物に含有させることが好ましい。
【0044】
本発明のウレアーゼ阻害剤は、尿素からウレアーゼの作用でアンモニアが発生する場所であれば特に制限なく使用することができる。
【0045】
本発明のウレアーゼ阻害剤(おむつかぶれ防止剤)は、おむつ、ティッシュ、おしり拭き、衛生用シート等に含有させたり、ウェットティッシュの薬剤、洗浄剤等として使用することができる。ウレアーゼ阻害剤のおむつへの含有は、例えば、ウレアーゼ阻害剤を含有する液体状の組成物をおむつ(布、紙、不繊布等)に塗布または浸漬して乾燥することにより行うことができる。また、ウレアーゼ阻害剤を含有する粉末状の組成物をおむつに混合することや、ウレアーゼ阻害剤を含有する組成物をローションに配合し、そのローションをおむつに塗布することもできる。
【0046】
本発明のウレアーゼ阻害剤をトップシート/液吸収部/バックシートの構成からなる使い捨ての紙おむつに使用する場合は、トップシートにウレアーゼ阻害剤を含有させることが好ましい。ウレアーゼ阻害剤のトップシート(質量)に対する添加量は、有効成分が化合物のときは、化合物で0.00001〜1質量%、有効成分が抽出物のときは、抽出物で0.0001〜10質量%とするのが好ましい。
【0047】
本発明のウレアーゼ阻害剤をウェットティッシュに使用する場合は、有効成分が化合物のときは、その化合物を0.00001〜1質量%、有効成分が抽出物のときは、その抽出物を0.0001〜10質量%、ウェットティッシュに含有させることが好ましい。
【0048】
一方、本発明のウレアーゼ阻害剤をアンモニアに起因する下痢、胃潰瘍等の防止に使用する場合、ウレアーゼ阻害剤は、顆粒剤、細粒剤、錠剤、カプセル剤等の剤形で使用することができるとともに、食品に添加すること、あるいは健康食品素材、ペットフード素材、医薬品原料等として使用することも可能である。
【0049】
なお、ここでいう「食品」とは、栄養素を1種以上含む天然物および加工品をいい、あらゆる飲食物を含むものとする。本発明のウレアーゼ阻害剤を添加し得る食品の具体例としては、チョコレート、ビスケット、飴菓子等の菓子類、ジュース等の清涼飲料、牛乳、ヨーグルト等の乳酸飲料などが挙げられる。
【0050】
上記の場合、ウレアーゼ阻害剤には、本発明の効果を損なわない範囲で、食品、医薬品、医薬部外品、化粧品、ペット用素材等に一般的に用いられている各種成分、例えば結合剤、吸収促進剤、滑沢剤、乳化剤、界面活性剤、酸化防止剤、防腐剤、着色剤、香料、甘味料等を配合することができる。また、本発明のウレアーゼ阻害剤は、他のウレアーゼ阻害剤や、リパーゼ阻害剤、プロテアーゼ阻害剤等と組み合わせて用いることもできる。
【0051】
本発明のウレアーゼ阻害剤の投与量は、有効成分であるフラボン類、フラボノール類、ジヒドロフラボノール類およびカテキン類の総量に換算して、通常一日あたり0.01〜10,000mg/kg(体重)、好ましくは0.1〜1,000mg/kg(体重)である。1日量を1回から数回程度投与することができるが、投与量および投与頻度は、年齢、性別、個人差、病状等に応じて適宜変更することができる。
【0052】
【実施例】
以下、実施例により本発明をさらに具体的に説明するが、本発明の範囲はこれらの実施例に限定されるものではない。
【0053】
〔実施例〕
50質量%エタノールを用いて、ルテオリン(和光純薬工業社製)、バイカレイン(和光純薬工業社製)、アピゲニン(和光純薬工業社製)、ケンフェロール(和光純薬工業社製)、クエルセチン(和光純薬工業社製)、モリン(東京化成工業社製)、タキシフォリン(和光純薬工業社製)、アンペロプシン、(+)−カテキン(和光純薬工業社製)および(−)−エピカテキン(和光純薬工業社製)を溶解および希釈して、試料濃度8000〜800μg/mlの試料溶液をそれぞれ調製し、各試料溶液について、以下の方法でウレアーゼ活性阻害率を測定した。
【0054】
なお、アンペロプシンとしては、次のようにして藤茶から得た抽出物を使用した。
藤茶乾燥枝葉200gに水2000mlを加え、90℃にて1時間抽出を行った後、濾紙にて濾過し、抽出液Aを得た。また、抽出残渣に再び水2000mlを加え、同様に90℃で1時間加熱抽出を行った後、濾紙にて濾過し、抽出液Bを得た。抽出液Aと抽出液Bとを混合した抽出液(A+B)を、多孔性樹脂(三菱化学社製,HP−20)300mlを充填したガラスカラムに流して、アンペロプシンを主成分とするフラボノイド類を吸着させた。吸着させた多孔性樹脂に600mlの水を流して洗浄した後、80%エタノールを流して吸着成分を溶出させた。得られた溶出液を減圧下にて濃縮、乾燥し、藤茶抽出物(粉末)を得た。
【0055】
試料溶液100μl、ウレアーゼ(和光純薬工業社製,ナタマメ起源,19U/ml,0.1Mリン酸緩衝液(pH7.0))400μlおよびサリチル酸ナトリウム・ニトロプルシドナトリウム溶液(サリチル酸ナトリウム40g/l,ニトロプルシドナトリウム2g/l,0.1Mリン酸緩衝液(pH7.0))1500μlをよく混合し、37℃で15分間保管した。この酵素反応液に次亜塩素酸ナトリウム・水酸化ナトリウム溶液(5%次亜塩素酸ナトリウム20ml,水酸化ナトリウム15g/l)2mlを加えた後、37℃で10分間反応させた。この反応により生じたインドフェノールを、波長570nmの吸光度で測定した。また、コントロールとして、試料溶液の代わりに50質量%エタノールを加えたものについて、同様の操作と吸光度測定を行った。
【0056】
上記吸光度測定の結果から、下記の計算式によりウレアーゼ活性阻害率を算出した。
ウレアーゼ活性阻害率(%)=1−[(A1−A0)/(A3−A2)]×100
A0:試料溶液を添加した場合の吸光度;酵素反応開始前
A1:試料溶液を添加した場合の吸光度;酵素反応開始後
A2:コントロールを添加した場合の吸光度;酵素反応開始前
A3:コントロールを添加した場合の吸光度;酵素反応開始後
【0057】
試料溶液の試料濃度を20〜200μg/mlに段階的に変化させて、上記ウレアーゼ活性阻害率の測定を行い、阻害率が50%になる試料溶液の試料濃度(IC50)を求めた。結果を表1に示す。
【0058】
〔比較例〕
フラバノン類としてのリクイリチゲニン(和光純薬工業社製)およびナリンゲニン(和光純薬工業社製)、カルコン類としてのイソリクイリチゲニン(丸善製薬社製)およびリコカルコンA(丸善製薬社製)、イソフラボン類としてのダイゼイン(和光純薬工業社製)およびフォルモノネチン(和光純薬工業社製)についても、実施例と同様にしてウレアーゼ活性阻害率の測定を行った。結果を表1に示す。
【0059】
【表1】
【0060】
表1の結果から、フラボン類、フラボノール類、ジヒドロフラボノール類およびカテキン類は、強いウレアーゼ活性阻害効果が認められる。
【0061】
【発明の効果】
本発明によれば、ウレアーゼ活性阻害効果に優れ安全性の高いウレアーゼ阻害剤、糞尿によるアンモニア臭を効果的に抑制することのできる安全性の高いアンモニア臭抑制剤、およびアンモニアに起因するおむつかぶれを効果的に防止することのできる安全性の高いおむつかぶれ防止剤が得られる。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a urease inhibitor that inhibits the action of urease, an enzyme that catalyzes a reaction that generates ammonia from urea, an ammonia odor suppressor that suppresses ammonia odor from manure, and a diaper that prevents diaper rash caused by ammonia The present invention relates to a rash prevention agent.
[0002]
[Prior art]
Urease is an enzyme that catalyzes the reaction of urea reacting with water to produce ammonia and carbon dioxide. For example, urease produced by microorganisms present in feces causes the above enzyme reaction with urea contained in urine excreted outside the living body of humans and livestock to generate ammonia. Therefore, when human or livestock manure is left in the environment, the enzyme reaction occurs to generate ammonia, and the generated ammonia diffuses into the atmosphere and gives off a strong odor.
[0003]
In addition, when the above enzyme reaction occurs in a diaper soiled with manure, the generated ammonia increases the pH of the skin, thereby increasing the activity of proteases and lipases in the feces and inducing diaper rash.
[0004]
On the other hand, in the intestine, it is known that ammonia is generated by the action of urease produced by intestinal bacteria, and symptoms such as diarrhea are caused by the cytotoxicity of ammonia. In the stomach, it is known that ammonia is produced by the action of urease produced by Helicobacter pylori, a bacterium present in the stomach, and gastric ulcer is induced by the ammonia.
[0005]
Therefore, in a place where ammonia can be generated from urea, it is possible to prevent ammonia smell, diaper rash, diarrhea, gastric ulcer, etc. due to feces and urine if the production of ammonia can be suppressed by inhibiting the action of urease It becomes.
[0006]
As urease inhibitors, to date, hydroxam amphoteric surfactants (Japanese Patent Laid-Open No. 58-104276), chlorogenic acid (Japanese Patent Laid-Open No. 6-183389), Luscus, Guava, Maikai, Lubus, Artemisia, Tamarind, Plant extracts such as Yukinoshita, loquat and persimmon (Japanese Patent Laid-Open No. 8-19595) have been reported.
[0007]
[Problems to be solved by the invention]
However, among the above urease inhibitors, there are problems in terms of safety with respect to synthetic compounds such as hydroxamic amphoteric surfactants and chlorogenic acid, and there are few that have a sufficiently high urease activity inhibitory effect with respect to the above plant extracts. Is the current situation.
[0008]
The present invention has been made in view of such a situation, and an object thereof is to provide a urease inhibitor, an ammonia odor suppressor, and a diaper rash preventing agent that are excellent in urease activity inhibitory effect and highly safe. And
[0009]
[Means for Solving the Problems]
As a result of intensive studies to achieve the above object, the present inventors have found that flavones, flavonols, dihydroflavonols and catechins have a strong urease activity inhibitory effect.
[0010]
That is, the present invention comprises a urease inhibitor (ammonia ) characterized by containing as an active ingredient one or more compounds selected from the group consisting of luteolin, baicalein, apigenin, kaempferol, quercetin, morin and taxifolin. Except for odor control and gastric ulcer treatment) .
[0012]
Furthermore, the present invention is a diaper rash preventing agent used by being contained in a diaper, a wipe, a sanitary sheet or a wet tissue, and is selected from the group consisting of luteolin, baicalein, apigenin, kaempferol, quercetin, morin and taxifolin. The present invention provides a diaper rash preventing agent characterized by containing one or more compounds as active ingredients.
[0013]
In the present invention, the “plant or the extract of the plant” includes an untreated plant, a dried product of the plant, a crushed product, a pulverized product, a powder, an extract obtained by using the plant as an extraction raw material, a diluted solution of the extract, or The concentrate, the dried product obtained by drying the extract, or any of these crudely purified products or purified products are included.
[0015]
According to the urease inhibitor of the present invention, generation of ammonia can be suppressed by its strong urease activity inhibiting effect, and ammonia odor, diaper rash, diarrhea, gastric ulcer and the like due to feces can be effectively prevented. In addition, since the active ingredient of the urease inhibitor of the present invention is mainly extracted from plants subjected to drinking, edible, medicinal use, the urease inhibitor of the present invention is safer than synthetic compounds. It is highly probable and has a low possibility of adversely affecting the environment.
[0016]
Similarly, the ammonia odor suppressor of the present invention can suppress the generation of ammonia by its strong urease activity inhibitory effect, and can effectively suppress the ammonia odor caused by manure. Moreover, the diaper rash preventing agent of the present invention suppresses the generation of ammonia due to its strong urease activity inhibitory effect, and can effectively prevent diaper rash due to ammonia. Furthermore, since the active ingredients of the ammonia odor suppressor and diaper rash preventive agent of the present invention are mainly extracted from plants used for drinking, edible, medicinal use, etc., the ammonia odor suppressor and diaper of the present invention Anti-rash agents are safer than synthetic compounds and are less likely to adversely affect the environment.
[0017]
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, the present invention will be described in detail.
The urease inhibitor of the present invention can be used as a drug for the prevention and treatment of diarrhea, gastric ulcer and the like, and is used as the ammonia odor inhibitor of the present invention for the purpose of suppressing ammonia odor due to manure Since the present invention can be used as a diaper rash preventive agent of the present invention when it is intended to prevent diaper rash caused by ammonia, the present invention will be described mainly with respect to a urease inhibitor. .
[0018]
The active ingredient of the urease inhibitor of the present invention is one or more compounds selected from the group consisting of flavones, flavonols, dihydroflavonols and catechins.
[0019]
The flavones in the present invention are compounds having a skeleton represented by the following formula (1).
[Chemical 1]
[In the formula (1), R 1 , R 2 , R 3 , R 4 , R ′ 1 , R ′ 2 , R ′ 3 , R ′ 4 and R ′ 5 are each independently a hydrogen atom, hydroxyl group, methoxy Represents a group or a linear, branched or cyclic alkyl group having 4 to 10 carbon atoms. ]
[0020]
Specific examples of the flavones include luteolin (in the formula (1), R 2 , R 4 , R ′ 1 , R ′ 2 and R ′ 5 are hydrogen atoms, R 1 , R 3 , R ′ 3 and R ′ 4 is a hydroxyl group compound), baicalein (in formula (1), R 4 , R ′ 1 , R ′ 2 , R ′ 3 , R ′ 4 and R ′ 5 are hydrogen atoms, R 1 , R Compound in which 2 and R 3 are hydroxyl groups), apigenin (in the formula (1), R 2 , R 4 , R ′ 1 , R ′ 2 , R ′ 4 and R ′ 5 are hydrogen atoms, R 1 , R 3 and compounds in which R ′ 3 is a hydroxyl group).
[0021]
Among the flavones, in the formula (1), R 4 , R ′ 1 , R ′ 2 and R ′ 5 are a hydrogen atom or a linear, branched or cyclic alkyl group having 4 to 10 carbon atoms, particularly hydrogen. A compound which is an atom and R 1 and R 3 are a hydroxyl group or a methoxy group, particularly a hydroxyl group is preferred, and among them, luteolin, baicalein and apigenin are particularly preferred.
[0022]
The flavonols in the present invention are compounds having a skeleton represented by the following formula (2).
[Chemical formula 2]
[In the formula (2), R 1 , R 2 , R 3 , R 4 , R ′ 1 , R ′ 2 , R ′ 3 , R ′ 4 and R ′ 5 are each independently a hydrogen atom, hydroxyl group, methoxy Represents a group or a linear, branched or cyclic alkyl group having 4 to 10 carbon atoms. ]
[0023]
Specific examples of the flavonols include kaempferol (in formula (2), R 2 , R 4 , R ′ 1 , R ′ 2 , R ′ 4 and R ′ 5 are hydrogen atoms, and R 1 , R 3 And a compound in which R ′ 3 is a hydroxyl group), quercetin (in formula (2), R 2 , R 4 , R ′ 1 , R ′ 2 and R ′ 5 are hydrogen atoms, and R 1 , R 3 , R ′ 3 and a compound in which R ′ 4 is a hydroxyl group), morin (in the formula (2), R 2 , R 4 , R ′ 1 , R ′ 2 and R ′ 4 are hydrogen atoms, R 1 , R 3 , R '3 and R' compound 5 is a hydroxyl group), and the like.
[0024]
Among the flavonols, in formula (2), R 2 , R 4 , R ′ 1 and R ′ 2 are hydrogen atoms or linear, branched or cyclic alkyl groups having 4 to 10 carbon atoms, particularly hydrogen atoms. A compound in which R 1 , R 3 and R ′ 3 are a hydroxyl group or a methoxy group, particularly a hydroxyl group is preferred, and kaempferol, quercetin and morin are particularly preferred.
[0025]
The dihydroflavonols in the present invention are compounds having a skeleton represented by the following formula (3).
[Chemical 3]
[In the formula (3), R 1 , R 2 , R 3 , R 4 , R ′ 1 , R ′ 2 , R ′ 3 , R ′ 4 and R ′ 5 are each independently a hydrogen atom, hydroxyl group, methoxy Represents a group or a linear, branched or cyclic alkyl group having 4 to 10 carbon atoms. ]
[0026]
Specific examples of the dihydroflavonols include taxifolin (in the formula (3), R 2 , R 4 , R ′ 1 , R ′ 2 and R ′ 5 are hydrogen atoms, and R 1 , R 3 , R ′ 3 And R ′ 4 is a hydroxyl group), amperopsin (in the formula (3), R 2 , R 4 , R ′ 1 and R ′ 5 are hydrogen atoms, R 1 , R 3 , R ′ 2 , R ′ 3 and R ′ 4 are hydroxyl groups).
[0027]
Among the above-mentioned dihydroflavonols, in the formula (3), R 2 , R 4 , R ′ 1 and R ′ 5 are hydrogen atoms or linear, branched or cyclic alkyl groups having 4 to 10 carbon atoms, particularly hydrogen. A compound which is an atom and in which R 1 , R 3 , R ′ 3 and R ′ 4 are a hydroxyl group or a methoxy group, particularly a hydroxyl group is preferable, and taxifolin and amperopsin are particularly preferable.
[0028]
The catechins in the present invention are compounds having a skeleton represented by the following formula (4).
[Formula 4]
[In the formula (4), R 1 , R 2 , R 3 , R 4 , R ′ 1 , R ′ 2 , R ′ 3 , R ′ 4 and R ′ 5 are each independently a hydrogen atom, hydroxyl group, methoxy Represents a group or a linear, branched or cyclic alkyl group having 4 to 10 carbon atoms. ]
[0029]
Specific examples of the catechins include (+)-catechin (in the formula (4), R 2 , R 4 , R ′ 1 , R ′ 2 and R ′ 5 are hydrogen atoms, R 1 , R 3 , R ′ 3 and R ′ 4 are hydroxyl groups), (−)-epicatechin (in the formula (4), R 2 , R 4 , R ′ 1 , R ′ 2 and R ′ 5 are hydrogen atoms, R 1 , R 3 , R ′ 3 and R ′ 4 are compounds having a hydroxyl group, and (+)-catechin is in an epimer relationship in which the direction of the hydroxyl group bonded to the 3-position carbon atom is different. Can be mentioned.
[0030]
Among the catechins, in the formula (4), R 2 , R 4 , R ′ 1 , R ′ 2 and R ′ 5 are hydrogen atoms or linear, branched or cyclic alkyl groups having 4 to 10 carbon atoms. Particularly preferred are compounds which are hydrogen atoms, and R 1 , R 3 , R ′ 3 and R ′ 4 are a hydroxyl group or a methoxy group, particularly a hydroxyl group, and catechin and epicatechin are particularly preferred.
[0031]
Here, as an active ingredient of the urease inhibitor of the present invention, one compound may be selected from the above flavones, flavonols, dihydroflavonols and catechins, or two or more compounds ( Two or more compounds belonging to the same class may be selected).
[0032]
The flavones, flavonols, dihydroflavonols and catechins used as active ingredients of the urease inhibitor of the present invention can be extracted from plants containing one or more of these components.
[0033]
Specific examples of plants containing flavones, flavonols, dihydroflavonols or catechins include olives (Olea europaea), parsley (Petroselinum sativum), Scutellaria baicalensis, moss isola (Reseda luteola), honeysuckle (Lonicera japonica) ), Twilight (Engelhardtia chrysolepis), wisteria tea (Ampelopsis grossedentata), tea (Thea sinensis), maggot salicina (Quercus salicina) and the like.
[0034]
The constituent parts of the plant used as the extraction raw material are not particularly limited, and for example, constituent parts such as leaves, branches, roots, bark, seeds, etc. can be used as the extraction raw material. Is preferably used as an extraction raw material.
[0035]
Extracts of flavones, flavonols, dihydroflavonols or catechins from plants containing flavones, flavonols, dihydroflavonols or catechins can be used in the state after the plant is left raw or dried, Or it can obtain by grind | pulverizing using a grinder and using for solvent extraction. As a solvent used for extraction, water, a hydrophilic organic solvent, or a mixed solution of water and a hydrophilic organic solvent is preferably used in a temperature range from room temperature to the boiling point of the solvent.
[0036]
Examples of water that can be used as the extraction solvent include pure water, tap water, well water, mineral spring water, mineral water, hot spring water, spring water, fresh water, and the like, as well as water that has been subjected to various treatments. Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, adjustment of osmotic pressure, buffering, and the like. Therefore, the water that can be used as the extraction solvent in the present invention includes purified water, hot water, ion-exchanged water, physiological saline, phosphate buffer, phosphate buffered saline, and the like.
[0037]
Examples of hydrophilic organic solvents that can be used as the extraction solvent include lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol, propylene alcohol, and isopropyl alcohol; lower aliphatic ketones such as acetone and methyl ethyl ketone; 1,3-butylene glycol. C2-5 polyhydric alcohols such as propylene glycol, isopropylene glycol and glycerin, and the like. These hydrophilic organic solvents or a mixed solvent of hydrophilic organic solvent and water can be used.
[0038]
When a mixed solvent of water and a hydrophilic organic solvent is used as the extraction solvent, when the hydrophilic organic solvent is a lower alcohol, 1 to 90 parts by weight of the hydrophilic organic solvent with respect to 10 parts by weight of the water, the hydrophilic organic solvent Is a lower aliphatic ketone, 1 to 40 parts by weight of a hydrophilic organic solvent with respect to 10 parts by weight of water, and 10 to 90 parts by weight of a hydrophilic organic solvent with respect to 10 parts by weight of water when the hydrophilic organic solvent is a polyhydric alcohol. Is preferably blended.
[0039]
In the present invention, it is not necessary to employ a special extraction method for extracting flavones, flavonols, dihydroflavonols or catechins from plants, and the extraction can be performed using an arbitrary apparatus at room temperature or under reflux heating. it can. Specifically, the extraction raw material is put into a treatment tank filled with the extraction solvent, and is sometimes stirred to elute soluble components. Thereafter, filtration is performed to remove the extraction residue, and the resulting extract is concentrated and dried to obtain an extract containing flavones, flavonols, dihydroflavonols or catechins.
[0040]
The extraction conditions are usually about 40 minutes to 90 ° C. for about 30 minutes to 2 hours when water is used as the extraction solvent, and usually about 40 minutes when a mixed solvent of water and ethanol is used as the extraction solvent. It is about 30 minutes to 2 hours at -80 ° C. The extract obtained by extraction with a solvent can be used as it is as a component of a urease inhibitor as long as the extraction solvent is highly safe.
[0041]
The obtained extract can also be purified for the purpose of decolorization, deodorization, activity improvement, and the like. The purification means is not particularly limited, and examples thereof include activated carbon treatment, resin adsorption treatment, ion exchange resin treatment, and liquid-liquid countercurrent distribution. For example, a resin adsorption purification method in which a porous resin such as Sepa beads SP-207 and Diaion HP-20 (all manufactured by Mitsubishi Chemical Corporation) and a concentrated liquid are brought into contact with each other can be employed. In this case, the active ingredient adsorbed on the resin can be eluted with water, ethanol or the like.
[0042]
In the present invention, one or more compounds selected from the group consisting of flavones, flavonols, dihydroflavonols and catechins, or a group consisting of flavones, flavonols, dihydroflavonols and catechins are selected. A plant containing one or more compounds or an extract of the plant is used as an active ingredient of a urease inhibitor, but other ingredients having a urease inhibitory action can be added as necessary.
[0043]
The dosage form and form of the urease inhibitor of the present invention are not particularly limited. For example, when a urease inhibitor is used for suppression of ammonia odor due to excrement or prevention of diaper rash (when the urease inhibitor is used as an ammonia odor suppressor or diaper rash prevention agent), the urease inhibitor is liquid, gel-like, It can be used in the form of a powder or the like, and a urease inhibitor can also be blended in lotions, sprays, mousses and the like. Such urease inhibitors can contain, for example, components such as humectants, pH adjusters, stabilizers, surfactants, antioxidants, deodorants and antibacterial agents. When the urease inhibitor is in a liquid or gel form, when the active ingredient is a compound, the compound is 0.00001 to 1% by mass, and when the active ingredient is an extract, the extract is 0.0001. It is preferable to contain in 10 to 10 mass% use composition.
[0044]
The urease inhibitor of the present invention can be used without particular limitation as long as ammonia is generated from urea by the action of urease.
[0045]
The urease inhibitor (diaper rash prevention agent) of the present invention can be contained in diapers, tissues, wipes, sanitary sheets, etc., or used as a wet tissue medicine, cleaning agent, or the like. The urease inhibitor can be contained in the diaper by, for example, applying or dipping a liquid composition containing the urease inhibitor into a diaper (cloth, paper, non-woven cloth, etc.) and drying. Moreover, the powdery composition containing a urease inhibitor can be mixed with a diaper, the composition containing a urease inhibitor can be mix | blended with a lotion, and the lotion can also be apply | coated to a diaper.
[0046]
When the urease inhibitor of the present invention is used for a disposable paper diaper having a configuration of a top sheet / liquid absorbing portion / back sheet, it is preferable to contain the urease inhibitor in the top sheet. The amount of urease inhibitor added to the top sheet (mass) is 0.00001 to 1% by mass for the compound when the active ingredient is a compound, and 0.0001 to 10% by mass for the extract when the active ingredient is an extract. % Is preferable.
[0047]
When the urease inhibitor of the present invention is used in a wet tissue, when the active ingredient is a compound, the compound is 0.00001 to 1% by mass, and when the active ingredient is an extract, the extract is 0.0001. It is preferable to make it contain in 10-10 mass% wet tissue.
[0048]
On the other hand, when the urease inhibitor of the present invention is used to prevent diarrhea, gastric ulcer, etc. caused by ammonia, the urease inhibitor can be used in dosage forms such as granules, fine granules, tablets, capsules and the like. At the same time, it can be added to food, or used as a health food material, pet food material, pharmaceutical material, and the like.
[0049]
Here, “food” refers to natural products and processed products containing one or more nutrients, and includes all foods and drinks. Specific examples of foods to which the urease inhibitor of the present invention can be added include confectionery such as chocolate, biscuits and candy, soft drinks such as juice, and lactic acid beverages such as milk and yogurt.
[0050]
In the above case, the urease inhibitor has various components commonly used in foods, pharmaceuticals, quasi-drugs, cosmetics, pet materials, etc., as long as the effects of the present invention are not impaired, such as binders, Absorption accelerators, lubricants, emulsifiers, surfactants, antioxidants, preservatives, colorants, fragrances, sweeteners, and the like can be blended. The urease inhibitor of the present invention can also be used in combination with other urease inhibitors, lipase inhibitors, protease inhibitors and the like.
[0051]
The dosage of the urease inhibitor of the present invention is usually 0.01 to 10,000 mg / kg (body weight) per day in terms of the total amount of active ingredients flavones, flavonols, dihydroflavonols and catechins. It is preferably 0.1 to 1,000 mg / kg (body weight). The daily dose can be administered once to several times, but the dose and frequency of administration can be appropriately changed according to age, sex, individual differences, medical conditions, and the like.
[0052]
【Example】
EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples. However, the scope of the present invention is not limited to these examples.
[0053]
〔Example〕
Using 50% by mass ethanol, luteolin (manufactured by Wako Pure Chemical Industries), baicalein (manufactured by Wako Pure Chemical Industries), apigenin (manufactured by Wako Pure Chemical Industries), kaempferol (manufactured by Wako Pure Chemical Industries), quercetin (Manufactured by Wako Pure Chemical Industries, Ltd.), Morin (manufactured by Tokyo Chemical Industry Co., Ltd.), taxifolin (manufactured by Wako Pure Chemical Industries, Ltd.), amperopsin, (+)-catechin (manufactured by Wako Pure Chemical Industries, Ltd.) and (−)-epicatechin (Wako Pure Chemical Industries, Ltd.) was dissolved and diluted to prepare sample solutions with sample concentrations of 8000 to 800 μg / ml, and the urease activity inhibition rate of each sample solution was measured by the following method.
[0054]
In addition, as amperopsin, the extract obtained from Fuji tea as follows was used.
2000 ml of water was added to 200 g of dried wisteria leaves and extracted at 90 ° C. for 1 hour, followed by filtration with filter paper to obtain Extract A. Further, 2000 ml of water was added again to the extraction residue, and similarly, extraction was performed by heating at 90 ° C. for 1 hour, followed by filtration with filter paper to obtain Extract B. The extract (A + B) obtained by mixing the extract A and the extract B is passed through a glass column packed with 300 ml of a porous resin (manufactured by Mitsubishi Chemical Corporation, HP-20), and flavonoids containing amperopsin as a main component. Adsorbed. After washing the adsorbed porous resin with 600 ml of water, 80% ethanol was allowed to flow to elute the adsorbed components. The obtained eluate was concentrated and dried under reduced pressure to obtain a Fuji tea extract (powder).
[0055]
Sample solution 100 μl, urease (manufactured by Wako Pure Chemical Industries, Natsume origin, 19 U / ml, 0.1 M phosphate buffer (pH 7.0)) 400 μl and sodium salicylate / sodium nitroprusside solution (sodium salicylate 40 g / l, sodium nitroprusside) 1500 μl of 2 g / l, 0.1 M phosphate buffer (pH 7.0)) was mixed well and stored at 37 ° C. for 15 minutes. 2 ml of sodium hypochlorite / sodium hydroxide solution (20 ml of 5% sodium hypochlorite, 15 g / l of sodium hydroxide) was added to the enzyme reaction solution, followed by reaction at 37 ° C. for 10 minutes. Indophenol produced by this reaction was measured by absorbance at a wavelength of 570 nm. Further, as a control, the same operation and absorbance measurement were performed on a sample obtained by adding 50% by mass ethanol instead of the sample solution.
[0056]
From the results of the absorbance measurement, the urease activity inhibition rate was calculated by the following formula.
Urease activity inhibition rate (%) = 1-[(A1-A0) / (A3-A2)] × 100
A0: Absorbance when the sample solution is added; Before the enzyme reaction A1: Absorbance when the sample solution is added; After the enzyme reaction is started A2: Absorbance when the control is added; A3: Before the enzyme reaction is started A3: Control is added Absorbance in case: After starting enzyme reaction
The urease activity inhibition rate was measured by changing the sample concentration of the sample solution stepwise from 20 to 200 μg / ml, and the sample concentration (IC50) of the sample solution at which the inhibition rate was 50% was determined. The results are shown in Table 1.
[0058]
[Comparative Example]
Liquiritigenin (manufactured by Wako Pure Chemical Industries, Ltd.) and Naringenin (manufactured by Wako Pure Chemical Industries, Ltd.) as flavanones, isoliquiritigenin (manufactured by Maruzen Pharmaceutical Co., Ltd.) and Ricochalcone A (manufactured by Maruzen Pharmaceutical Co., Ltd.), isoflavones, For daidzein (manufactured by Wako Pure Chemical Industries, Ltd.) and formononetin (manufactured by Wako Pure Chemical Industries, Ltd.) as classes, urease activity inhibition rate was measured in the same manner as in the Examples. The results are shown in Table 1.
[0059]
[Table 1]
[0060]
From the results in Table 1, flavones, flavonols, dihydroflavonols and catechins have a strong urease activity inhibitory effect.
[0061]
【The invention's effect】
According to the present invention, a urease inhibitor having excellent urease activity inhibitory effect and high safety, a highly safe ammonia odor inhibitor capable of effectively suppressing ammonia odor due to manure, and diaper rash caused by ammonia A highly safe diaper rash preventing agent that can be effectively prevented is obtained.
Claims (2)
ルテオリン、バイカレイン、アピゲニン、ケンフェロール、クエルセチン、モリンおよびタキシフォリンからなる群から選ばれる1種または2種以上の化合物を有効成分として含有することを特徴とするおむつかぶれ防止剤。 A diaper anti-shock agent used in diapers, wipes, sanitary sheets or wet tissues,
An anti-diaper rash inhibitor comprising one or more compounds selected from the group consisting of luteolin, baicalein, apigenin, kaempferol, quercetin, morin and taxifolin as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002251692A JP4450355B2 (en) | 2002-08-29 | 2002-08-29 | Urease inhibitor, ammonia odor suppressor and diaper rash inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002251692A JP4450355B2 (en) | 2002-08-29 | 2002-08-29 | Urease inhibitor, ammonia odor suppressor and diaper rash inhibitor |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004091338A JP2004091338A (en) | 2004-03-25 |
JP2004091338A5 JP2004091338A5 (en) | 2005-10-06 |
JP4450355B2 true JP4450355B2 (en) | 2010-04-14 |
Family
ID=32058215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002251692A Expired - Fee Related JP4450355B2 (en) | 2002-08-29 | 2002-08-29 | Urease inhibitor, ammonia odor suppressor and diaper rash inhibitor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4450355B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102503925A (en) * | 2011-11-07 | 2012-06-20 | 吉首大学 | Flavenes (isoflavene) urease inhibitor and synthesis and purpose thereof |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2192178B1 (en) | 2007-09-20 | 2015-11-18 | Kao Corporation | B-glucuronidase inhibitor |
JP2010163363A (en) * | 2009-01-13 | 2010-07-29 | Kao Corp | Method for producing extract containing apigenin in high concentration |
WO2010146788A1 (en) | 2009-06-17 | 2010-12-23 | 花王株式会社 | Apigenin-containing composition |
JP5547946B2 (en) * | 2009-10-21 | 2014-07-16 | 花王株式会社 | Method for producing purified apigenin-containing extract |
JP5619484B2 (en) * | 2010-04-06 | 2014-11-05 | 花王株式会社 | Composition for suppressing urine odor production |
CN105712967B (en) * | 2016-02-04 | 2017-11-14 | 深伦生物科技(深圳)有限公司 | The method that dihydromyricetin and taxifolin are extracted from cogongrass cliff berry leaf |
US11812774B2 (en) | 2016-06-24 | 2023-11-14 | Suntory Holdings Limited | Composition for browning inhibition and use of same |
CN110526891A (en) * | 2019-09-17 | 2019-12-03 | 湖北省农业科学院中药材研究所 | A method of texifolin is isolated and purified and identified from vine tea tissue |
CN110526889A (en) * | 2019-09-17 | 2019-12-03 | 湖北省农业科学院中药材研究所 | A method of myricetin is isolated and purified and identified from vine tea tissue |
CN110526890A (en) * | 2019-09-17 | 2019-12-03 | 湖北省农业科学院中药材研究所 | A method of dihydromyricetin is isolated and purified and identified from vine tea tissue |
CN114804967B (en) | 2022-05-23 | 2023-05-09 | 中国科学院沈阳应用生态研究所 | Application of Farnesene in the Preparation of Plant Source Urease Inhibitors |
CN114887106A (en) * | 2022-05-31 | 2022-08-12 | 华南理工大学 | Bio-based reaction type odor removing liquid and preparation method and application thereof |
CN115211491A (en) * | 2022-06-06 | 2022-10-21 | 遵义医科大学珠海校区 | Application of broadleaf holly leaf in preparation of jack bean urease inhibitor |
CN116059228A (en) * | 2023-02-10 | 2023-05-05 | 遵义医科大学珠海校区 | Application of astilbin in preparation of jerusalem artichoke urease inhibitor |
-
2002
- 2002-08-29 JP JP2002251692A patent/JP4450355B2/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102503925A (en) * | 2011-11-07 | 2012-06-20 | 吉首大学 | Flavenes (isoflavene) urease inhibitor and synthesis and purpose thereof |
CN102503925B (en) * | 2011-11-07 | 2014-02-26 | 吉首大学 | Flavene (isoflavin) urease inhibitors and their synthesis and use |
Also Published As
Publication number | Publication date |
---|---|
JP2004091338A (en) | 2004-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4450355B2 (en) | Urease inhibitor, ammonia odor suppressor and diaper rash inhibitor | |
Popović et al. | Effect of celery (Apium graveolens) extracts on some biochemical parameters of oxidative stress in mice treated with carbon tetrachloride | |
JP5092145B2 (en) | Anti-norovirus agent and composition containing the same | |
JP6387467B2 (en) | Mangosteen extract or composition for preventing or ameliorating periodontal disease comprising alpha and gamma mangosteen as active ingredients | |
KR102394664B1 (en) | Method for manufacturing green tea extract, and green tea extract therefrom | |
JP4901024B2 (en) | 8-OHdG (8-hydroxydeoxyguanosine) production inhibitor | |
JP4947505B2 (en) | Deodorants | |
JP4420358B1 (en) | Hyaluronic acid production promoter | |
JP2003048844A (en) | Urease activity inhibitor | |
JP2003081744A (en) | Antioxidant | |
JP6719475B2 (en) | Urease activity inhibitor | |
KR20220120521A (en) | Deodorant composition comprising Quillaia saponaria | |
Sharma et al. | Role of plant extract in the inhibition of dental caries | |
JP2010526125A (en) | New use of hibiscus, especially pharmaceutical use | |
JP2015071623A (en) | Agent for maintaining health of periodontal tissue comprising oleuropein and degraded product thereof | |
KR101610894B1 (en) | Taste-masked granules containing vitamin C | |
JP3897862B2 (en) | Method for producing oral bad breath deodorant | |
JP4315496B2 (en) | Hydrogen sulfide production inhibitor from sulfate-reducing bacteria and hydrogen sulfide production inhibitor composition containing the same | |
KR100597702B1 (en) | Deodorant composition and sanitary pad containing same | |
JP2007051096A (en) | Oral composition | |
JP2005139074A (en) | Inhibitor of production of enterotoxin by staphylococcus aureus | |
JP2003055179A (en) | Composition for spraying into oral cavity | |
CN1520308A (en) | New application of polyphenol of natural phant as well as medication and/or health products containing polyphenol of natural plant | |
KR20140065220A (en) | Citrus extract for inhibiting halitosis and composition having the same | |
KR102347243B1 (en) | Composition for anti-virus comprising Quillaia saponaria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050517 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050517 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090128 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090330 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090330 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100120 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100122 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130205 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |